Last updated 2026-07-27
- Went public on Nasdaq (ICCM), Aug 2021
- Raised $15M PIPE led by Alpha Capital, Dec 2020
- Raised $5.5M PIPE led by Epoch Partners, Jan 2015
Total raised
$25.0M
Last: PIPE 2026-06
Stage
Public
Founded
2006
Headcount
66
HQ
Caesarea, Israel
Sector
Health Tech & Life Sciences
About
IceCure Medical is a commercial-stage medical device company focused on transforming healthcare by providing minimally invasive cryoablation treatment options for benign and malignant tumors. Their flagship product, the ProSense® Cryoablation System, uses liquid nitrogen to destroy tumors by freezing them, offering an alternative to surgical removal for various indications including breast, kidney, bone, and lung cancer. The company emphasizes empowering patients with treatment choices and providing a safe, effective, and convenient outpatient procedure with minimal scarring. IceCure Medical's technology is supported by clinical data and has regulatory approvals worldwide.
Funding history · 13 rounds · $25.0M total
2026-05
Follow-on PO
Undisclosed
2025-07
Follow-on PO
Undisclosed
2025-01
Follow-on PO
Undisclosed
2024-01
Follow-on PO
Undisclosed
2022-12
Follow-on PO
Undisclosed
2021-12
Follow-on PO
Undisclosed
2020-12
PIPE
$15.0M
★ Alpha Capital★ Clover Wolf Capital
2020-07
Follow-on PO
Undisclosed
2019-01
Follow-on PO
Undisclosed
2015-01
PIPE
$5.5M
★ Epoch Partners
2013-07
Follow-on PO
Undisclosed
2011-01
Follow-on PO
Undisclosed
2008-06
B Round
$4.5M
★ Giza Venture Capital★ Docor International Management
Headcount over time
From 28 (2018-07) to 72 (2026-03) · +44 (+157%) · 60 points · source: Finder history + radar grounding
Q&A
- What is IceCure Medical's primary business?
- IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of benign and malignant tumors by freezing them. Their flagship product is the ProSense® Cryoablation System.
- When did IceCure Medical go public on NASDAQ?
- IceCure Medical went public on NASDAQ in August 2021.
- What was the amount raised in IceCure Medical's most recent public offering?
- In May 2026, IceCure Medical raised $4,339,697 in a Public Offering.
- What was a significant regulatory approval for IceCure Medical in July 2024?
- In July 2024, the U.S. Food and Drug Administration granted regulatory clearance to IceCure for its next-generation XSense™ Cryoablation System with CryoProbes.
- What were the key findings from IceCure's ICE3 clinical trial for breast cancer?
- In September 2024, the 5-year results from IceCure's ICE3 trial, published in the Annals of Surgical Oncology Journal, demonstrated a 96.3% recurrence-free rate for early-stage, low-risk breast cancer patients who underwent ProSense cryoablation with endocrine therapy.
- What was the outcome of the FDA advisory panel meeting for ProSense® in November 2024?
- In November 2024, an FDA advisory panel voted favorably on the benefit-risk profile of IceCure's ProSense® cryoablation system for early-stage, low-risk breast cancer.
- What was a significant patent allowance IceCure Medical received in October 2024?
- In October 2024, IceCure received a Notice of Allowance from the U.S. Patent and Trademark Office for its next-generation cryoablation system.
- What was the outcome of the ICESECRET study for kidney tumors, as reported in May 2026?
- In May 2026, data presented at ECIO 2026 from the ICESECRET study showed IceCure's ProSense® cryoablation system to be safe and effective in the destruction of kidney tumors with an 89.4% recurrence-free rate.
- What was a notable development regarding IceCure Medical's Nasdaq compliance in June 2026?
- In June 2026, IceCure Medical announced a 1-for-30 reverse share split to support Nasdaq compliance.
- What was the reported sales growth for ProSense® in North America in IceCure Medical's 2024 financial results?
- In March 2025, IceCure Medical reported 42% growth in ProSense® cryoablation sales in North America for its 2024 financial results.
Team · 1
Hezi Himmelfarb
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesRaw Materials
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 PatentsVerified
Tags
femtechminimally-invasivemedical-deviceswomen-healthultrasoundhospitalssurgeonsradiologyoncologybiopsycancerhealthcare-providerswomenclinicscancer-therapytreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Legal name | IceCure Medical Ltd. |
|---|---|
| Founded | 2006 |
| Employees (exact) | 66 |
| Offices | Nanuet |
| Market cap | $42.1M |
| Status reason | Public on TASE on Feb 2011;Public on NASDAQ on Aug 2021; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2021-08 | Nasdaq | ICCM | |
| Public Offering | 2022-12 | Nasdaq | ICCM | $14.5M |
| Registered Direct Offering | 2026-03 | Nasdaq | ICCM | $4.0M |
| Private Placement | 2026-06 | Nasdaq | ICCM | $5.5M |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513787804 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2006-01-25 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | האשל 7 קיסריה |